Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 – ResearchByMarkets.com

PUNE, India, September 05, 2018 /ResearchByMarkets/— Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018


This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features dormant and discontinued products.

Diabetes refers to a group of metabolic diseases that result from defects in insulin secretion, insulin action or both of these. Type I diabetes is an autoimmune disease in which the pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. There are 263 products in development for this indication.

Type 2 diabetes, however, results from a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. Type 2 diabetes is more closely related to lifestyle choices such as diet and exercise habits than type I diabetes, with the majority of patients being overweight or obese. There are 574 products in development for this indication.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. There are 10 products in development for this indication.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. There are seven products in development for this indication.

Molecular targets acted on by products in development for diabetes and associated metabolic conditions include the insulin receptor, glucagon-like peptide 1 (GLP-1) receptor, glucagon receptor and glucokinase. Companies operating in this pipeline space include Novo Nordisk, Eli Lilly and Zealand Pharma



– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


Companies Mentioned:
Adocia SAS
Aegis Therapeutics LLC
AiCuris GmbH & Co KG
Akcea Therapeutics Inc
Allist Shanghai Pharmaceutical Technology Co Ltd
Amarantus Bioscience Holdings Inc
Amarna Therapeutics BV
Amgen Inc
apceth Biopharma GmbH
Aphios Corp
Apodemus AB
Arecor Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Atlantic Bio Sci LLC
AusBio Ltd
Avadel Pharmaceuticals Plc
Axxam SpA
Bayer AG
Beta-Cell NV
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioLineRx Ltd
BioLingus AG
BioRestorative Therapies Inc
BirchBioMed Inc
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Therapeutics Inc
Braasch Biotech LLC
Bristol-Myers Squibb Co
BTB Pharma AB
C4X Discovery Holdings PLC
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Caladrius Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Cardax Inc
Carmot Therapeutics Inc
Cellix Bio Pvt Ltd
Celon Pharma SA
Center Laboratories Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
Cinnagen Co
CJ HealthCare Corp
CohBar Inc
Compugen Ltd
Concenter BioPharma Silkim Ltd
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dance Biopharm Inc
DanDrit Biotech A/S
Delpor Inc
Denceptor Therapeutics Ltd
Diabetology (Products) Ltd
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiaVacs Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
Dompe Farmaceutici SpA
Dong-A Socio Holdings Co Ltd
Elcelyx Therapeutics Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Energenesis Biomedical Co Ltd
Ensol Biosciences Inc
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
EpiVax Inc
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Generex Biotechnology Corp
GeNeuro SA
Genexine Inc
Genfit SA
Genmedica Therapeutics SL
Genovate Biotechnology Co LTD
Geropharm LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
HitGen LTD
Hyundai Pharmaceutical Co Ltd
ImCyse SA
Immupharma Plc
Immuron Ltd
Inflazome Ltd
Innovative Targeting Solutions Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Intas Pharmaceuticals Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Intrexon Corp
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Just Biotherapeutics Inc
Kadimastem Ltd
Kadmon Corp LLC
Kamada Ltd
Kasiak Research Pvt Ltd
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Laboratorios Silanes SA de CV
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
LipimetiX Development Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Magnus Life Ltd
MannKind Corp
Maruho Co Ltd
Medesis Pharma SA
MedImmune LLC
Medlab Clinical Ltd
Medtronic Plc
Medy-Tox Inc
Merck & Co Inc
Meridigen Biotech Co Ltd
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Mitsubishi Chemical Holdings Corp
Mitsubishi Tanabe Pharma Corp
Naia Ltd
Neovacs SA
Neurimmune Holding AG
NGM Biopharmaceuticals Inc
Novapeutics LLC
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orgenesis Inc
Original BioMedicals Co Ltd
OSE Immunotherapeutics
Palatin Technologies Inc
Panacea Biotec Ltd
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
Pathfinder Cell Therapy Inc
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
Pharmasum Therapeutics AS
Pila Pharma AB
Poxel SA
Prometheon Pharma LLC
ProMetic Life Sciences Inc
Prothena Corp Plc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Renova Therapeutics Inc
Reset Therapeutics Inc
Rezolute Inc
Rubius Therapeutics Inc
Saniona AB
Sanwa Kagaku Kenkyusho Co Ltd
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co Ltd
ScandiCure AB
Semma Therapeutics Inc
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sotio AS
Sprint Bioscience AB
Sumitomo Dainippon Pharma Co Ltd
Suzuken Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Teijin Pharma Ltd
Tetragenetics Inc
The Medicines Company
Theracos Inc
Thermalin Diabetes LLC
Tiziana Life Sciences Plc
Toleranzia AB
Tolerion Inc
Topas Therapeutics GmbH
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
TTY Biopharm Company Ltd
Twoxar Inc
Uni-Bio Science Group Ltd
Unicyte AG
Ventria Bioscience
ViaCyte Inc
Vichem Chemie Research Ltd
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
XBiotech Inc
XERIS Pharmaceuticals Inc
XL-protein GmbH
XuanZhu Pharma Co Ltd
Yabao Pharmaceutical Group Co Ltd
Yuhan Corp
Zafgen Inc
Zealand Pharma AS

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.